{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:53:08Z","timestamp":1792705988994,"version":"4.5.0"},"posted":{"date-parts":[[2025,10,24]]},"group-title":"Health Informatics","reference-count":36,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,2,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Hypermobile Ehlers-Danlos Syndrome (hEDS) is a complex, underdiagnosed connective tissue disorder characterized by widespread symptoms affecting multiple organ systems. Recent clinical observations suggest that individuals with hEDS may be at increased risk for persistent symptoms following COVID-19, commonly referred to as Long COVID. Using data from over 19 million patients across the United States, we examined associations between hEDS, COVID-19 infection, Long COVID, and related chronic conditions.<\/jats:p>\n                <jats:p>We identified just over 25,000 individuals with hEDS and estimated a prevalence of approximately 1 in 800, which is higher than previously recognized. While rates of COVID-19 infection were similar between patients with hEDS and matched controls, patients with hEDS were significantly more likely to develop Long COVID. This risk was especially elevated among patients with hEDS with overlapping conditions commonly seen in post-viral syndromes, including autonomic dysfunction, immune dysregulation, and chronic fatigue. Specifically, individuals with postural orthostatic tachycardia, mast cell-related symptoms, or chronic fatigue syndrome had the highest rates of Long COVID.<\/jats:p>\n                <jats:p>Temporal diagnostic analyses revealed that many patients received an hEDS diagnosis only after a COVID-19 infection, suggesting that viral illness may exacerbate or reveal previously unrecognized symptoms. Patients with hEDS also exhibited higher odds of having additional risk factors for severe or prolonged illness, including chronic lung and autoimmune conditions, depression, and cerebrovascular disease.<\/jats:p>\n                <jats:p>These findings highlight a previously unrecognized vulnerability in patients with hEDS and underscore the need for greater clinical awareness of their heightened risk for persistent post-COVID illness. Improved screening, earlier diagnosis, and integrated care pathways are urgently needed to support this complex and underserved patient population.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Author summary<\/jats:title>\n                  <jats:p>We studied patients with hypermobile Ehlers-Danlos Syndrome (hEDS), a connective tissue condition that affects joints, skin, and many body systems. This condition is often misunderstood or overlooked, leaving many people undiagnosed. During the COVID-19 pandemic, people with hEDS appeared to experience more long-term symptoms after infection, a condition often called Long COVID. Here, we analyzed the health records of millions of patients in the United States to better understand post-viral outcomes.<\/jats:p>\n                  <jats:p>Patients with hEDS were more likely to be diagnosed with Long COVID compared to similar patients without hEDS. This was especially true for those who also had conditions such as chronic fatigue, immune conditions, or issues with heart rate and blood pressure regulation. In many cases, people were diagnosed with hEDS for the first time only after they had COVID-19, suggesting the virus may worsen or reveal symptoms that had been previously missed.<\/jats:p>\n                  <jats:p>Our findings show that hEDS may be more common than previously thought and that such patients face higher risks after COVID-19. Greater awareness and earlier recognition of hEDS could improve care for many patients with complex, long-lasting symptoms<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.10.22.25338573","type":"posted-content","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T23:40:12Z","timestamp":1761349212000},"source":"Crossref","is-referenced-by-count":1,"title":["Understanding Comorbidities in Hypermobile Ehlers-Danlos Syndrome: Could a Viral Infection Unmask the Disorder?"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-7530","authenticated-orcid":false,"given":"Megan L.","family":"Pearson","sequence":"first","affiliation":[{"name":"Department of Dermatology; Gates Institute, University of Colorado Anschutz Medical Campus, Aurora CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan J.","family":"Laraway","sequence":"additional","affiliation":[{"name":"Department of Genetics; University of North Carolina, Chapel Hill NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen R.","family":"Elias","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Genetics, Children\u2019s Hospital Colorado, Aurora CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganna","family":"Bilousova","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Gates Institute, University of Colorado Anschutz Medical Campus, Aurora CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Haendel","sequence":"additional","affiliation":[{"name":"Department of Genetics; University of North Carolina, Chapel Hill NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026021912450746000_2025.10.22.25338573v2.1","unstructured":"Miklovic T , Sieg. VC . Ehlers-Danlos Syndrome. In: StatPearls [Internet]. 29 May 2023 [cited 3 Jun 2025]. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549814\/"},{"key":"2026021912450746000_2025.10.22.25338573v2.2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31552"},{"key":"2026021912450746000_2025.10.22.25338573v2.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2018.02.018"},{"key":"2026021912450746000_2025.10.22.25338573v2.4","unstructured":"Hypermobile Ehlers-Danlos syndrome (a.k.. Ehlers-Danlos syndrome Type III Ehlers-Danlos syndrome hypermobility type): clinical description natural history."},{"key":"2026021912450746000_2025.10.22.25338573v2.5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.mayocpiqo.2024.04.001","article-title":"Phenotypic clusters and multimorbidity in hypermobile Ehlers-Danlos syndrome","volume":"8","year":"2024","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2026021912450746000_2025.10.22.25338573v2.6","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31546"},{"key":"2026021912450746000_2025.10.22.25338573v2.7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/pmt-2022-0050","article-title":"Multidisciplinary chronic pain management strategies in patients with Ehlers-Danlos syndromes","volume":"13","year":"2023","journal-title":"Pain Manag"},{"key":"2026021912450746000_2025.10.22.25338573v2.8","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31554"},{"key":"2026021912450746000_2025.10.22.25338573v2.9","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31543"},{"key":"2026021912450746000_2025.10.22.25338573v2.10","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31951"},{"key":"2026021912450746000_2025.10.22.25338573v2.11","doi-asserted-by":"crossref","first-page":"rkae134","DOI":"10.1093\/rap\/rkae134","article-title":"Similarities and differences in self-reported symptoms and comorbidities between hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders","volume":"8","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"2026021912450746000_2025.10.22.25338573v2.12","unstructured":"People O. HEDS. In: The Ehlers Danlos Society [Internet]. 2 Jul 2024 [cited 3 Jun 2025]. Available: https:\/\/www.ehlers-danlos.com\/heds\/"},{"key":"2026021912450746000_2025.10.22.25338573v2.13","unstructured":"People O. What is HSD? In: The Ehlers Danlos Society [Internet]. 15 Mar 2017 [cited 18 Jun 2025]. Available: https:\/\/www.ehlers-danlos.com\/what-is-hsd\/"},{"key":"2026021912450746000_2025.10.22.25338573v2.14","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15927"},{"key":"2026021912450746000_2025.10.22.25338573v2.15","doi-asserted-by":"crossref","unstructured":"Ishiguro H , Yagasaki H , Horiuchi Y . Ehlers-Danlos syndrome in the field of psychiatry: A review. Front Psychiatry. 2021;12: 803898.","DOI":"10.3389\/fpsyt.2021.803898"},{"key":"2026021912450746000_2025.10.22.25338573v2.16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajmg.c.31555","article-title":"Mast cell disorders in Ehlers-Danlos syndrome","volume":"175","year":"2017","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2026021912450746000_2025.10.22.25338573v2.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.03.022"},{"key":"2026021912450746000_2025.10.22.25338573v2.18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11882-024-01126-0","article-title":"Using the right criteria for MCAS","volume":"24","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"2026021912450746000_2025.10.22.25338573v2.19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.iac.2018.04.004","article-title":"Association of postural tachycardia syndrome and Ehlers-Danlos syndrome with mast cell activation disorders","volume":"38","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"2026021912450746000_2025.10.22.25338573v2.20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/JXX.0000000000000900","article-title":"Clinical trajectory of hypermobile Ehlers-Danlos syndrome\/hypermobility spectrum disorders in older adults","volume":"35","year":"2023","journal-title":"J Am Assoc Nurse Pract"},{"key":"2026021912450746000_2025.10.22.25338573v2.21","unstructured":"Re-Writing Natural History Pain Related Symptoms Joint Hypermobility Syndrome\/ Ehlers-Danlos Syndrome, Hypermobility Type."},{"key":"2026021912450746000_2025.10.22.25338573v2.22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ajmg.a.62640","article-title":"Longitudinal analysis of symptoms in the Ehlers-Danlos syndromes","volume":"188","year":"2022","journal-title":"Am J Med Genet A"},{"key":"2026021912450746000_2025.10.22.25338573v2.23","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0511-2"},{"key":"2026021912450746000_2025.10.22.25338573v2.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031365"},{"key":"2026021912450746000_2025.10.22.25338573v2.25","doi-asserted-by":"crossref","first-page":"e63613","DOI":"10.1002\/ajmg.a.63613","article-title":"Patient experiences of receiving a diagnosis of hypermobile Ehlers-Danlos syndrome","volume":"194","year":"2024","journal-title":"Am J Med Genet A"},{"key":"2026021912450746000_2025.10.22.25338573v2.26","doi-asserted-by":"crossref","unstructured":"Schubart JR , Schaefer EW , Knight DRT , Mills SE , Francomano CA . Estimates of the excess cost burden of Ehlers-Danlos syndromes: a United States MarketScan\u00ae claims database analysis. Front Public Health. 2024;12: 1365712.","DOI":"10.3389\/fpubh.2024.1365712"},{"key":"2026021912450746000_2025.10.22.25338573v2.27","doi-asserted-by":"crossref","unstructured":"Ganesh R , Munipalli B . Long COVID and hypermobility spectrum disorders have shared pathophysiology. Front Neurol. 2024;15: 1455498.","DOI":"10.3389\/fneur.2024.1455498"},{"key":"2026021912450746000_2025.10.22.25338573v2.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjph-2023-000478"},{"key":"2026021912450746000_2025.10.22.25338573v2.29","doi-asserted-by":"crossref","unstructured":"Grach SL , Dudenkov DV , Pollack B , Fairweather D , Aakre CA , Munipalli B , et al. Overlapping conditions in Long COVID at a multisite academic center. Front Neurol. 2024;15: 1482917.","DOI":"10.3389\/fneur.2024.1482917"},{"key":"2026021912450746000_2025.10.22.25338573v2.30","doi-asserted-by":"publisher","DOI":"10.5281\/ZENODO.15556955"},{"key":"2026021912450746000_2025.10.22.25338573v2.31","doi-asserted-by":"publisher","DOI":"10.5281\/ZENODO.15556955"},{"key":"2026021912450746000_2025.10.22.25338573v2.32","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v042.i08"},{"key":"2026021912450746000_2025.10.22.25338573v2.33","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocad057"},{"key":"2026021912450746000_2025.10.22.25338573v2.34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"lifelines: survival analysis in Python","volume":"4","year":"2019","journal-title":"J Open Source Softw"},{"key":"2026021912450746000_2025.10.22.25338573v2.35","unstructured":"Hakim A. Hypermobile Ehlers-Danlos Syndrome. In: Adam MP , Bick S , Mirzaa GM , Pagon RA , Wallace SE , Amemiya A , editors. GeneReviews. Seattle (WA): University of Washington, Seattle; 2004."},{"key":"2026021912450746000_2025.10.22.25338573v2.36","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-022-09280-1"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.22.25338573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T20:45:16Z","timestamp":1771533916000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.10.22.25338573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":36,"URL":"https:\/\/doi.org\/10.1101\/2025.10.22.25338573","relation":{},"subject":[],"published":{"date-parts":[[2025,10,24]]},"subtype":"preprint"}}